PBAC Public Summary Documents - November 2009

Public summary documents relating to the November 2009 PBAC meeting

Page last updated: 01 August 2011

• Agalsidase alfa (ghu) and beta (rch) infusions, literature review; Replagal®, Fabrazyme®, November 2009
• Alglucosidase alfa, powder for I.V. infusion, 50 mg, Myozyme®, November 2009
• Aprepitant, pack containing 1 capsule 125 mg and 2 capsules 80 mg, Emend®, November 2009
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for I.M. injection, 100 units, Botox®, November 2009
• Dabigatran etexilate mesilate, capsules, 75 mg and 110 mg (base), Pradaxa®, November 2009
• Darunavir, tablets, 150 mg and 300 mg (as ethanolate), Prezista®, November 2009
• Diclofenac sodium with misoprostol, tablet, 50 mg–200 micrograms, Arthrotec® 50, November 2009
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, November 2009
• Dutasteride, capsule, 500 micrograms, Avodart®, November 2009
• Everolimus, tablet, 5 mg and 10 mg, Afinitor®, November 2009
• Ganirelix, solution for injection, 250 micrograms in 0.5ml (as acetate), single use pre-filled syringe, Orgalutran®, November 2009
• Goserelin acetate, subcutaneous implant, 3.6 mg (base) in pre-filled injection syringe, Zoladex Implant®, November 2009
• Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec®, November 2009
• Lacosamide, tablets, 50 mg, 100 mg, 150 mg and 200 mg, oral solution, 15 mg per mL, Vimpat®, November 2009
• Maraviroc, tablets, 150 mg and 300 mg, Celsentri®, November 2009
• Methoxy polyethylene glycol-epoetin beta, solution for injection, 30 micrograms in 0.3 mL, 50 micrograms in 0.3 mL, 75 micrograms in 0.3 mL, 100 micrograms in 0.3 mL, 120 micrograms in 0.3 mL, 200 micrograms in 0.3 mL and 360 micrograms in 0.6 mL, single use pre-filled syringe, Mircera®, November 2009
• Nebivolol hydrochloride, tablets, titration pack containing 42 tablets 1.25mg and 14 tablets 5 mg, 1.25 mg, 5 mg and 10 mg (base), Nebilet®, November 2009
• Omalizumab (rch), powder for injection, 150 mg, Xolair®, November 2009
• Pemetrexed disodium, powder for I.V. infusion, 100 mg and 500 mg (base), Alimta®, November 2009
• Rizatriptan benzoate, tablet, 5 mg and 10 mg (base), wafer, 5 mg and 10 mg (base), Maxalt®, November 2009
• Tenofovir disoproxil fumarate with emtricitabine and efavirenz, tablet, 300 mg – 200 mg – 600 mg, Atripla®, November 2009
• Tocilizumab, solution for I.V. infusion, 80 mg in 4 mL, 200 mg in 10 mL and 400 mg in 20 mL, Actemra® , November 2009
• Ustekinumab (rmc), solution for injection, 45 mg in 0.5 mL, Stelara®, November 2009
• Varenicline tartrate, tablet, 1 mg, Champix®, November 2009
• Zoledronic acid, solution for I.V. infusion, 5 mg (as monohydrate) in 100 mL, Aclasta®, (Men), November 2009
• Zoledronic acid, solution for I.V. infusion, 5 mg (as monohydrate) in 100 mL, Aclasta®, (CIO) November 2009
• Zoledronic acid, solution for I.V. infusion, 5 mg (as monohydrate) in 100 mL, Aclasta®, (Paget), November 2009